Home Alzheimer’s Disease FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma

FDA Approves Nivolumab-Ipilimumab Combo for Hepatocellular Carcinoma

The FDA approved the combination use of nivolumab (Opdivo) plus ipilimumab (Yervoy) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Nexavar), according to Bristol Myers Squibb (BMS).

The agency approved a dose of 1 mg/kg of nivolumab and 3 mg/kg of ipilimumab under accelerated approval, the only dual immunotherapy approved by the FDA in this setting.

“We recognize there is a critical need to provide patients with aggressive forms of cancer, like HCC, new treatment options that may offer clinically meaningful and ultimately durable responses,” Adam Lenkowsky, general manager and head, U.S., Oncology, Immunology, Cardiovascular, Bristol Myers Squibb, said in a press release. “Today’s announcement builds on our legacy in pioneering immunotherapy treatments and is an important step in our commitment to…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

Recent Comments